Picture Credit score: © Crystal mild – inventory.adobe.com
Key takeaways
Enhertu plus pertuzumab confirmed a 44% discount in illness development or loss of life versus the present standard-of-care THP routine.
The mix remedy achieved a median PFS of 40.7 months, setting a brand new potential first-line normal for HER2-positive metastatic breast most cancers.
DESTINY-Breast09 highlights environment friendly trial execution throughout international websites, emphasizing the significance of well-structured multicenter design in oncology trials.
AstraZeneca and Daiichi Sankyo have shared constructive information from the Part III DESTINY-Breast09 scientific trial (NCT04784715) of Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab as a first-line remedy for sufferers with HER2-positive metastatic breast most cancers.1
The Enhertu-pertuzumab mixture demonstrated a statistically vital and clinically significant enchancment in progression-free survival (PFS) in comparison with a taxane, trastuzumab, and pertuzumab (THP) routine. Detailed information from the DESTINY-Breast09 research have been shared on the 2025 American Society of Scientific Oncology (ASCO) Annual Assembly.
Sturdy PFS profit noticed throughout a number of affected person subgroups
Outcomes from a prespecified interim evaluation confirmed that Enhertu and pertuzumab decreased the danger of illness development or loss of life by 44% versus THP. The Enhertu-pertuzumab mixture achieved a median PFS of 40.7 months, in comparison with 6.9 months for THP. The PFS profit for Enhertu and pertuzumab was constant throughout a number of affected person subgroups together with de novo or recurrent illness, hormone receptor standing, and PIK3CA mutation standing.
In a press launch, Sara Tolaney, MD, MPH, chief of the division of breast oncology, Dana-Farber Most cancers Institute and principal investigator within the trial, stated: “Sufferers with HER2-positive metastatic breast most cancers usually expertise illness development round two years after initiating standard-of-care first-line remedy. With a median progression-free survival of greater than three years, the DESTINY-Breast09 outcomes present trastuzumab deruxtecan mixed with pertuzumab has the potential to turn into a brand new first-line normal of look after these sufferers.”
Excessive goal response price and sturdy responses reported
The Enhertu-pertuzumab duo had a confirmed goal response price (ORR) of 85.1% versus 78.6% for THP. There have been 58 full responses with Enhertu plus pertuzumab in comparison with 33 with THP. Enhertu plus pertuzumab demonstrated a median length of response (DOR) of 39.2 months, whereas THP demonstrated 26.4 months.
In response to AstraZeneca, general survival (OS) information weren’t mature on the time of this evaluation. Nevertheless, the interim information present an early development favoring the Enhertu-pertuzumab mixture in comparison with THP.
World trials and extra research assist Enhertu’s broad potential
The Part III DESTINY-Breast09 trial is a worldwide, multicenter, randomized, open-label research enrolling sufferers at a number of websites in Africa, Asia, Europe, North America, and South America. The research options arms for Enhertu as monotherapy, Enhertu plus pertuzumab, and THP. A complete of 1,157 sufferers have been randomized in a 1:1:1 ratio throughout the three arms.2
The research’s major endpoint is PFS, plus key secondary endpoints together with investigator-assessed PFS, OS, ORR, length of response, investigator-assessed time to second development or loss of life, patient-reported tolerability, pharmacokinetics, and security.
AstraZeneca initially shared information of Enhertu plus pertuzumab demonstrating a major enchancment in PFS in sufferers with HER2-positive metastatic breast most cancers earlier in April.2
In a press launch from the time, Susan Galbraith, govt vp, oncology hematology R&D, AstraZeneca, stated “That is the primary trial in additional than a decade to exhibit superior efficacy throughout a broad HER2-positive metastatic breast most cancers affected person inhabitants in comparison with the present first-line normal of care. This can be a vital milestone for sufferers and units the inspiration for Enhertu together with pertuzumab as an essential remedy possibility within the first-line HER2-positive setting.”
Enhertu can be being evaluated within the Part III DESTINY-Breast11 trial (NCT05113251) in sufferers with high-risk, domestically superior HER2-positive early-stage breast most cancers. In Might, AstraZeneca shared that Enhertu adopted by normal HER2-targeted remedy demonstrated a major enchancment in pathologic full response (pCR) charges in comparison with present standard-of-care chemotherapy.3
DESTINY-Breast11 randomized 927 sufferers 1:1:1 to obtain both eight cycles of Enhertu monotherapy, 4 cycles of Enhertu after which 4 cycles of THP, or 4 cycles of dose-dense doxorubicin and cyclophosphamide adopted by 4 cycles of THP. The trial’s major endpoint is pCR, plus secondary endpoints together with event-free survival, invasive disease-free survival, OS, and security.
References
1. ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab decreased the danger of illness development or loss of life by 44% vs. THP as 1st-line remedy in sufferers with HER2-positive metastatic breast most cancers in DESTINY-Breast09 Part III trial. Information launch. AstraZeneca. June 2, 2025. Accessed June 2, 2025. https://www.businesswire.com/information/residence/20250602557687/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-by-44-vs.-THP-as-1st-line-therapy-in-patients-with-HER2-positive-metastatic-breast-cancer-in-DESTINY-Breast09-Part-III-trial
2. DESTINY-Breast09 Trial Exhibits Enhertu Plus Perjeta Considerably Improves Survival in HER2-Optimistic Metastatic Breast Most cancers. Utilized Scientific Trials. April 21, 2025. Accessed June 2, 2025. https://www.appliedclinicaltrialsonline.com/view/enhertu-perjeta-survival-her2-metastatic-breast-cancer
3. DESTINY-Breast11 Trial Exhibits Enhertu Plus THP Considerably Improves Response Charges in Excessive-Threat HER2-Optimistic Early Breast Most cancers. Utilized Scientific Trials. Might 7, 2025. Accessed June 2, 2025. https://www.appliedclinicaltrialsonline.com/view/destiny-breast11-enhertu-her2-positive-early-breast-cancer
